MedTrace Logo

Histology of Implantation Biopsies and Kidney Allograft Outcomes

NCT03155763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2017-05-18

No results posted yet for this study

Summary

The morphology of transplanted kidney is considered to be important for graft outcomes in early and late posttransplant period. Individual histological lesions at the time of kidney transplantation, such as sclerosis of glomeruli, vascular narrowing and interstitial fibrosis, and composite histological lesions, which integrate histopathological findings in different compartments, showed association with suboptimal graft outcomes. However there are no consistent association between individual or composite lesions and transplant outcomes. Some possible explanations for such inconsistent results are non-uniformity in grading histological lesions or in defining graft outcomes. Furthermore, studies vary in terms of patient selection, and some results are not corrected for covariates. It is also unclear, whether acute biopsy features associated with the donor kidney can provide prognostic information, in addition to the chronic lesions? This single-center study aimed to evaluate which acute and chronic histological lesions and composite histological scores in donor kidney intraoperative biopsies alone or in combination with clinical variables are best associated with short- and long-term kidney graft outcomes, such as impairment of early kidney allograft function, immunological acute kidney allograft rejection, pyelonephritis, allograft function at 1, 3, 6, 12 months, 2, 3, 4 and 5 years, and graft survival at 1 and 5 years.

Conditions

  • Kidney Graft Dysfunction

Interventions

PROCEDURE

Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy

Sponsors & Collaborators

  • Andriy Trailin

    lead OTHER

Principal Investigators

  • Andriy V Trailin, MD, DSc · State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-01
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03155763 on ClinicalTrials.gov